Inhibitor – Page 3

Pfizer’s Sasanlimab Shows 32% Reduction in Bladder Cancer Risk But Misses Secondary Endpoints in Phase 3 CREST Trial

6 months ago talkbio0Tagged BCG Vaccine, Event-Free Survival, Inhibitor, Invasive, Malignant neoplasm of urinary bladder, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Overall Survival, PDCD1 gene, Phase 3 CREST trial, Sasanlimab, subcutaneous administration

Sasanlimab (PD-1 inhibitor), Bladder cancer risk reduction, Phase 3 CREST trial, BCG combination therapy, Non-muscle invasive bladder cancer (NMIBC), Event-free survival (EFS), Overall survival (OS) endpoint missed, Subcutaneous administration

Roche’s WRN Inhibitor Shows Promising Early Results in MSI-H Tumors at AACR25

6 months ago talkbio0Tagged AACR25, Cancer Research, High-Frequency Microsatellite Instability, Inhibitor, Neoplasms, Roche (company), Werner Syndrome

Roche, WRN inhibitor, MSI-H tumors, AACR25, cancer research, oncology

Akeso’s PD-1 inhibitor notches inaugural FDA nod for nasopharyngeal cancer

6 months ago talkbio0Tagged Akeso, Akeso 's, Anniko, Approved, Inhibitor, Nasopharyngeal carcinoma, PDCD1 gene, United States Food and Drug Administration

United States Food and Drug Administration, Approved, Akeso, Nasopharyngeal carcinoma, PDCD1 gene, Inhibitor, Akeso ‘s, Anniko

Novartis Halts Phase 2 Osteoarthritis Study of ADAMTS-5 Inhibitor Due to Lack of Pain Relief

6 months ago talkbio0Tagged ADAMTS-5, cartilage degradation, Clinical Trial Termination, Degenerative polyarthritis, Drug Development, Inhibitor, Knee pain, M6495, Novartis, Pain, QUC398

Novartis, phase 2 trial, osteoarthritis, knee pain, ADAMTS-5 inhibitor, QUC398, M6495, clinical trial termination, pain relief, cartilage degradation, drug development

Third Harmonic Bio to Liquidate, Selling Key Urticaria Drug Asset THB335

6 months ago talkbio0Tagged biopharma exit strategy, Chronic Spontaneous Urticaria, clinical-stage, CSU, drug sales, Inhibitor, KIT, Kit device, shareholder, THB335, Third Harmonic Bio liquidation, value maximization

Third Harmonic Bio liquidation , THB335 drug sale , chronic spontaneous urticaria (CSU) , KIT inhibitor , biopharma exit strategy , clinical-stage biotech , shareholder value maximization